MMR immunohistochemistry
A test of four DNA repair proteins to assess dMMR status.
Not a diagnosis and not final medical advice. Must be reviewed by a doctor.
Purpose of the test
- Assess DNA repair status.
- Becomes the basis for additional examination if the results are abnormal.
Informs decisions
- Suitability of immunotherapy categories.
- The need for genetic counseling in certain cases.
How the test is done
Antibody staining for MLH1, MSH2, MSH6, and PMS2 in tumor tissue.
- Sample type
- Block tumor tissue
- Estimated result time
- Generally several working days.
Limitations
- Loss of a single protein needs to be interpreted along with additional tests.
- Results may differ between network blocks.
Related
Cancer types
Markers tested
Not displayed
TanyaKanker does not display test-cost estimates. Ask the laboratory or facility providing the test for cost details directly.
Sources
- NCI Dictionary of Cancer Terms(lembaga)
Next steps
These suggestions come from links between entries in TanyaKanker's database, not from a medical judgement. Each suggestion includes why it appears.
To check
- Stomach Cancer
Cancer type
Reason: Memerlukan pemeriksaan
- Immunotherapy
Treatment category
Reason: Memerlukan pemeriksaan
- MSI / MMR
Biomarker
Reason: Diperiksa melalui
- Check medical report completeness
Tool
Reason: Prepare documents that still need confirmation
- Prepare questions for your doctor
Tool
Reason: Bring clear questions to the next conversation
What you can do
- Upload medical reports
Build a case summary in twelve steps
Reason: Often the most useful next step after reading this page
- Request a second opinion
Review of the treatment plan
Reason: Relevant when a treatment plan is being considered
- Consult a navigator
A request is recorded with this page context
Reason: For asking the next step directly
Recently updated
- Leukemia
Cancer page
Date: Data revision 2026-09-10
- Brain Cancer
Cancer page
Date: Data revision 2026-09-10
- Pancreatic Cancer
Cancer page
Date: Data revision 2026-09-10
- Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
NCT03191149 - Phase 2
Date: Registry update in the last 30 days (2026-10-15)
Want to follow changes on this topic? Save the page or follow the topic so it is easy to find again. View saved items.
Prepare for your next consultation
Use the free six-question tool to prepare questions for your doctor.